MedCap (Q1 review): Strong EBITA Growth, Poised for Acquisitions - Redeye

Redeye updates its estimates and valuation following MedCap’s Q1 2026 report. Organic growth was 4%, a normal level for the company, which, together with 10% organic growth and FX changes, resulted in 13% total growth. The adj. EBITDA was SEK110m, a growth of 30%, thanks to a 3%-point margin expansion.

Länk till analysen i sin helhet: https://www.redeye.se/research/1164037/medcap-q1-review-strong-ebita-growth-poised-for-acquisitions?utm_source=finwire&utm_medium=RSS